PMV PHARMACEUTICALS INC (PMVP)

Company Profile

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 63 full-time employees. The company went IPO on 2020-09-25. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. The company is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.

Company Info

PMV PHARMACEUTICALS INC

One Research Way

Princeton NEW JERSEY 08512

P: 16096426664

CEO: David H. Mack

Employees: 63

Website: https://www.pmvpharma.com/